Mutschler E, Spahn H, Kirch W
Br J Clin Pharmacol. 1984;17 Suppl 1(Suppl 1):51S-57S. doi: 10.1111/j.1365-2125.1984.tb02428.x.
The degrees of interactions between the H2-receptor antagonists, cimetidine and ranitidine, and several beta-adrenoceptor blockers were investigated in healthy volunteers following 7 days of oral monotherapy with penbutolol, propranolol, metoprolol, pindolol and atenolol, and after co-administration with each of the H2-receptor antagonists. The kinetic parameters of unmetabolised penbutolol and penbutolol glucuronide were unaffected, whereas the levels of 4-hydroxypenbutolol and 4-hydroxypenbutolol glucuronide were significantly reduced. Furthermore, cimetidine led to a marked increase in propranolol and metoprolol plasma levels. During co-administration with cimetidine, pindolol plasma levels were only slightly raised, whereas the pharmacokinetics of atenolol were not affected. With regard to pharmacodynamics, the inhibition of exercise-induced tachycardia by each of the beta-adrenoceptor blockers was not affected by cimetidine. Ranitidine did not alter atenolol plasma levels, but did raise the peak plasma concentration of metoprolol by about 30%. It is concluded that cimetidine interactions do occur and can be predicted for substances metabolised by the cytochrome P-450 pathway.
在健康志愿者中,研究了在分别口服喷布洛尔、普萘洛尔、美托洛尔、吲哚洛尔和阿替洛尔7天进行单一疗法后,以及在与每种H2受体拮抗剂联合给药后,H2受体拮抗剂西咪替丁和雷尼替丁与几种β肾上腺素受体阻滞剂之间的相互作用程度。未代谢的喷布洛尔和喷布洛尔葡糖醛酸的动力学参数未受影响,而4 - 羟基喷布洛尔和4 - 羟基喷布洛尔葡糖醛酸的水平显著降低。此外,西咪替丁导致普萘洛尔和美托洛尔的血浆水平显著升高。在与西咪替丁联合给药期间,吲哚洛尔的血浆水平仅略有升高,而阿替洛尔的药代动力学未受影响。在药效学方面,每种β肾上腺素受体阻滞剂对运动诱发心动过速的抑制作用不受西咪替丁影响。雷尼替丁未改变阿替洛尔的血浆水平,但使美托洛尔的血浆峰浓度升高约30%。得出的结论是,西咪替丁确实会发生相互作用,并且对于通过细胞色素P - 450途径代谢的物质,这种相互作用是可以预测的。